>

Neil Osheroff

  • Vanderbilt University

    Osheroff Lab contributed data leading to FDA approval of treatment for gonorrhea

    Crucial research by Neil Osheroff and his lab led to FDA approval of the first new class of antibacterial drugs in decades. The drug, gepotidacin, developed by GlaxoSmithKline under the brand name Blujepa, is now approved to treat uncomplicated urinary tract infections and gonorrhea. Read More

    April 28, 2025

  • Vanderbilt University

    Vanderbilt biochemists contribute to breakthrough discovery of first new antibacterial class in decades

    Led by Neil Osheroff, Vanderbilt researchers are the first to undertake a systematic analysis of the mechanism of action of gepotidacin, a first-in-class triazaacenaphthylene antibacterial, against its targets in Escherichia coli—the type II topoisomerases gyrase and topoisomerase IV—and the mechanistic basis for drug resistance. E. coli is the etiological agent of most urinary tract infections. Read More

    March 28, 2024

  • Vanderbilt University

    Osheroff receives Distinguished Teacher Award from Association of American Medical Colleges

    As a professor of biochemistry and medicine at Vanderbilt University School of Medicine for more than 40 years, Osheroff is the longest serving course director currently teaching medical students. He also codirects the preclerkship phase of the medical school curriculum and leads the Master Science Teachers cohort, a role established in 2007 to recognize VUSM’s outstanding basic science educators. Through his teaching, he has helped medical students at VUSM and across the globe acquire the basic science skills and knowledge they need to thrive in clinical practice, according to the AAMC. Read More

    October 31, 2023

  • Vanderbilt University

    Crowe, Osheroff honored by AAMC

    Vanderbilt's James E. Crowe, Jr, MD, and Neil Osheroff, PhD, are among 12 individuals honored by the Association of American Medical Colleges during its 2023 Awards Recognition Event. Read More

    October 30, 2023

  • Vanderbilt University

    Osheroff wins prestigious MILES Award

    Neil Osheroff received the Mentoring, Innovation, and Leadership in Educational Scholarship Award at the annual Asia Pacific Medical Education Conference that took place in May. Read More

    July 7, 2023

  • Vanderbilt University

    Correctly copying DNA

    New research into the enzyme topoisomerase II sheds light on how it helps DNA replicate properly. Read More

    March 14, 2019

  • Confronting TB resistance

    Confronting TB resistance

    Vanderbilt researchers describe how certain tuberculosis treatments work and suggest these medications may overcome the threat of drug-resistant tuberculosis. Read More

    June 11, 2018

  • Vanderbilt University

    Novel insights to antibiotic targets

    New mechanistic details about the DNA-unwinding activity of antibacterial protein targets could lead to the design of better antibiotic medicines. Read More

    September 29, 2017

  • Vanderbilt University

    Slight chemical change may improve TB treatments: study

    One small chemical change to an existing antibacterial drug results in a compound that is more effective against its target enzyme in tuberculosis, Vanderbilt researchers have discovered. Read More

    February 11, 2016

  • Vanderbilt University

    Anticancer olive compounds

    Compounds found in olives and olive oil have anticancer activity, which may contribute to the cancer preventive properties attributed to the Mediterranean diet. Read More

    July 27, 2015